Tags

Type your tag names separated by a space and hit enter

Effects of hemodialysis on blood fatty acids.
Physiol Rep. 2020 01; 8(2):e14332.PR

Abstract

Omega-3 (n-3) fatty acids have beneficial cardiovascular effects, perhaps also in chronic kidney disease (CKD) patients. A low omega-3 index is an independent cardiovascular risk factor in end-stage renal disease (ESRD) dialysis patients. However, the plasma measurements invariably ignore circulating blood cells, including the preponderant erythrocytes (RBCs). We measured fatty acids (HPLC-MS lipidomics) in all components of the circulating blood, since RBC n-3 fatty acid status has been linked to cardiovascular disease and mortality. We studied 15 healthy persons and 15 CKD patients undergoing regular hemodialysis treatments. While total fatty acid levels differed significantly in RBCs from healthy controls and CKD patients, the hemodialysis treatment had no effect on plasma or RBC fatty acid levels. No changes occurred in the percentage of eicosapentaenoic acid (C20:5 n-3, EPA) and docosahexaenoic acid (C22:6 n-3; DHA) (omega-3 quotient) in RBC membrane fatty acids. Nonetheless, hemodialysis treatments increased plasma levels of various total fatty acids, namely C12:0, C14:0, C16:0, C20:2 n-6, C20:4 n-6, and C22:6 n-3 (DHA), while plasma levels of free fatty acids were unchanged. These data suggest that despite significant changes in fatty acids signatures between healthy persons and CKD patients, hemodialysis does not alter RBC n-3 fatty acid status, including the omega-3 quotient. The dialysis treatment per se does not appear to be responsible for a lower omega-3 index in CKD patients.

Authors+Show Affiliations

Experimental and Clinical Research Center (ECRC), A joint institution of the Charité Medical Faculty and Max Delbrück Center (MDC) for Molecular Medicine, Berlin, Germany. HELIOS Klinikum Berlin-Buch, Berlin, Germany.LIPIDOMIX GmbH, Berlin, Germany.LIPIDOMIX GmbH, Berlin, Germany.Experimental and Clinical Research Center (ECRC), A joint institution of the Charité Medical Faculty and Max Delbrück Center (MDC) for Molecular Medicine, Berlin, Germany. Universitätsmedizin Greifswald, Klinik für Geriatrie, Greifswald, Germany.Experimental and Clinical Research Center (ECRC), A joint institution of the Charité Medical Faculty and Max Delbrück Center (MDC) for Molecular Medicine, Berlin, Germany.

Pub Type(s)

Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

31981323

Citation

Gollasch, Benjamin, et al. "Effects of Hemodialysis On Blood Fatty Acids." Physiological Reports, vol. 8, no. 2, 2020, pp. e14332.
Gollasch B, Dogan I, Rothe M, et al. Effects of hemodialysis on blood fatty acids. Physiol Rep. 2020;8(2):e14332.
Gollasch, B., Dogan, I., Rothe, M., Gollasch, M., & Luft, F. C. (2020). Effects of hemodialysis on blood fatty acids. Physiological Reports, 8(2), e14332. https://doi.org/10.14814/phy2.14332
Gollasch B, et al. Effects of Hemodialysis On Blood Fatty Acids. Physiol Rep. 2020;8(2):e14332. PubMed PMID: 31981323.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of hemodialysis on blood fatty acids. AU - Gollasch,Benjamin, AU - Dogan,Inci, AU - Rothe,Michael, AU - Gollasch,Maik, AU - Luft,Friedrich C, PY - 2019/11/19/received PY - 2019/12/03/revised PY - 2019/12/04/accepted PY - 2020/1/26/entrez PY - 2020/1/26/pubmed PY - 2021/1/2/medline KW - chronic kidney disease KW - dialysis KW - erythrocytes KW - exercise KW - fatty acids KW - lipidomics SP - e14332 EP - e14332 JF - Physiological reports JO - Physiol Rep VL - 8 IS - 2 N2 - Omega-3 (n-3) fatty acids have beneficial cardiovascular effects, perhaps also in chronic kidney disease (CKD) patients. A low omega-3 index is an independent cardiovascular risk factor in end-stage renal disease (ESRD) dialysis patients. However, the plasma measurements invariably ignore circulating blood cells, including the preponderant erythrocytes (RBCs). We measured fatty acids (HPLC-MS lipidomics) in all components of the circulating blood, since RBC n-3 fatty acid status has been linked to cardiovascular disease and mortality. We studied 15 healthy persons and 15 CKD patients undergoing regular hemodialysis treatments. While total fatty acid levels differed significantly in RBCs from healthy controls and CKD patients, the hemodialysis treatment had no effect on plasma or RBC fatty acid levels. No changes occurred in the percentage of eicosapentaenoic acid (C20:5 n-3, EPA) and docosahexaenoic acid (C22:6 n-3; DHA) (omega-3 quotient) in RBC membrane fatty acids. Nonetheless, hemodialysis treatments increased plasma levels of various total fatty acids, namely C12:0, C14:0, C16:0, C20:2 n-6, C20:4 n-6, and C22:6 n-3 (DHA), while plasma levels of free fatty acids were unchanged. These data suggest that despite significant changes in fatty acids signatures between healthy persons and CKD patients, hemodialysis does not alter RBC n-3 fatty acid status, including the omega-3 quotient. The dialysis treatment per se does not appear to be responsible for a lower omega-3 index in CKD patients. SN - 2051-817X UR - https://www.unboundmedicine.com/medline/citation/31981323/Effects_of_hemodialysis_on_blood_fatty_acids_ L2 - https://doi.org/10.14814/phy2.14332 DB - PRIME DP - Unbound Medicine ER -